Login to Your Account

Verastem dodged Zydelig woe in PI3K by way of prophylaxis

By Randy Osborne
Staff Writer

Wednesday, December 20, 2017

For phosphoinositide 3-kinase (PI3K) drug development, "the black eye came very much from the Gilead experience with Zydelig last year," acknowledged Verastem Inc. CEO Robert Forrester, but that bruise was healed by the "totality, consistency and magnitude" of phase III data offered by his firm with duvelisib in CLL at the ASH meeting in Atlanta.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription